EGFR mutations in non‑small cell lung cancer – treatment options
05/2019
MUDr. Daniel Krejčí; MUDr. Jana Krejčí; doc. MUDr. Norbert Pauk, Ph.D.
Klinika pneumologie 3. LF UK a Nemocnice Na Bulovce, Praha
SUMMARY
Worldwide, lung cancer is one of the most common oncological disease. Targeted analysis of the mutation status in non-small cell lung carcinoma detects 10-15 % of patients with a mutated epidermal growth factor receptor gene, whose presence is significant prognostically and therapeutically.1 Diagnosis is based on molecular-genetic methods.2 Depending on the patient's performance status and type of mutation, the patient is indicated for therapy with tyrosine kinase inhibitors, which in this group of patients promise a good response to treatment with a favorable safety profile.13
Key words
epidermal growth factor receptor, tyrosine kinase inhibitor
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...